Prevalence and determinants of exocrine pancreatic insufficiency among older adults:: Results of a population-based study

被引:77
作者
Rothenbacher, D
Löw, M
Hardt, PD
Klör, HU
Ziegler, H
Brenner, H
机构
[1] Univ Heidelberg, German Ctr Res Ageing, Dept Epidemiol, DE-69115 Heidelberg, Germany
[2] Univ Giessen, Dept Med 3, Giessen, Germany
[3] Gesundheitsberichterstattung Saarland Krebsregist, Saarbrucken, Germany
关键词
elastase-1; exocrine pancreatic insufficiency; observational study; prevalence; risk factors;
D O I
10.1080/00365520510023116
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective. The prevalence and main determinants of exocrine pancreatic insufficiency were investigated in a large population- based sample of older adults by measuring pancreatic elastase-1 in stool. Material and methods. The study comprised 914 participants aged 50 to 75 years recruited by their general practitioner during a general health examination. All participants and their physicians were asked to fill out a standardized questionnaire which contained information on socio-demographic and lifestyle factors as well as medical history. Native stool was examined for pancreatic elastase-1 with a commercially available ELISA ( ScheBo(R) Tech, Giessen, Germany). Results. Overall, 524 women and 390 men aged 50 to 75 years ( mean age 61.9 years) were included in the analysis. In total, 105 (11.5%) of the 914 subjects showed signs of exocrine pancreatic insufficiency (EPI) with <= 200 mu g elastase-1/g stool, and 47 (5.1%) subjects showed signs of a severe exocrine pancreatic insufficiency (SEPI, < 100 mu g elastase-1/g stool). There was a clear increase in EPI with age. Patients taking angiotensin-converting enzyme ( ACE) inhibitors had a lower prevalence than subjects without this medication; these associations persisted after adjustment for covariates. Conclusions. Prevalence of EPI increases with age and seems to be tentatively higher in men than in women. However, smoking seems to be an independent risk factor for EPI and SEPI whereas ACE-inhibitor intake might be a protective factor. The latter finding may even point to new options in the treatment of chronic pancreatitis.
引用
收藏
页码:697 / 704
页数:8
相关论文
共 31 条
  • [1] Fecal pancreatic elastase 1 is inaccurate in the diagnosis of chronic pancreatitis
    Amann, ST
    Bishop, M
    Curington, C
    Toskes, PP
    [J]. PANCREAS, 1996, 13 (03) : 226 - 230
  • [2] Association between ACE inhibitors and acute pancreatitis in the elderly
    Cheng, RMS
    Mamdani, M
    Jackevicius, CA
    Tu, K
    [J]. ANNALS OF PHARMACOTHERAPY, 2003, 37 (7-8) : 994 - 998
  • [3] Pancreatic function testing
    Chowdhury, RS
    Forsmark, CE
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (06) : 733 - 750
  • [4] Díte P, 2001, EUR J GASTROEN HEPAT, V13, P749
  • [5] DOERR W, 1964, Verh Dtsch Ges Inn Med, V70, P718
  • [6] DOMINGUEZMUNOZ JE, 1995, AM J GASTROENTEROL, V90, P1834
  • [7] Fecal elastase-1 as a test for pancreatic function: a review
    Dominici, R
    Franzini, C
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (04) : 325 - 332
  • [8] The epidemiology of alcohol-induced pancreatitis
    Dufour, MC
    Adamson, MD
    [J]. PANCREAS, 2003, 27 (04) : 286 - 290
  • [9] Fecal elastase 1 determination in chronic pancreatitis
    Gullo, L
    Ventrucci, M
    Tomassetti, P
    Migliori, M
    Pezzilli, R
    [J]. DIGESTIVE DISEASES AND SCIENCES, 1999, 44 (01) : 210 - 213
  • [10] High prevalence of exocrine pancreatic insufficiency in diabetes mellitus - A multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients
    Hardt, PD
    Hauenschild, A
    Nalop, J
    Marzeion, AM
    Jaeger, C
    Teichmann, J
    Bretzel, RG
    Hollenhorst, M
    Kloer, HU
    [J]. PANCREATOLOGY, 2003, 3 (05) : 395 - 402